FI934134A - Herpes simplex-vaccin innehaollande hsv-glykoprotein gd och 3-deacylerad monofosforyllipid a - Google Patents

Herpes simplex-vaccin innehaollande hsv-glykoprotein gd och 3-deacylerad monofosforyllipid a Download PDF

Info

Publication number
FI934134A
FI934134A FI934134A FI934134A FI934134A FI 934134 A FI934134 A FI 934134A FI 934134 A FI934134 A FI 934134A FI 934134 A FI934134 A FI 934134A FI 934134 A FI934134 A FI 934134A
Authority
FI
Finland
Prior art keywords
deacylerad
glykoprotein
monophosphoryllipid
innehaollande
vaccin
Prior art date
Application number
FI934134A
Other languages
English (en)
Other versions
FI107881B (fi
FI934134A0 (fi
Inventor
Myriam Francotte
Jean-Paul Prieels
Moncef Slaoui
Nathalie Marie- Garcon-Johnson
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10691946&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI934134(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of FI934134A publication Critical patent/FI934134A/fi
Publication of FI934134A0 publication Critical patent/FI934134A0/fi
Application granted granted Critical
Publication of FI107881B publication Critical patent/FI107881B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FI934134A 1991-03-21 1993-09-21 Menetelmä Herpes simplex-rokotteen valmistamiseksi, joka sisältää HSV-glykoproteiinia GD ja 3-deasyloitua monofosforyylilipidi A:ta FI107881B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9105992A GB9105992D0 (en) 1991-03-21 1991-03-21 Vaccine
GB9105992 1991-03-21
PCT/EP1992/000592 WO1992016231A1 (en) 1991-03-21 1992-03-17 HERPES SIMPLEX VACCINE COMPRISING HSV GLYCOPROTEIN gD AND 3 dEACYLATED MONOPHOSPHORYL LIPID A
EP9200592 1992-03-17

Publications (3)

Publication Number Publication Date
FI934134A true FI934134A (fi) 1993-09-21
FI934134A0 FI934134A0 (fi) 1993-09-21
FI107881B FI107881B (fi) 2001-10-31

Family

ID=10691946

Family Applications (1)

Application Number Title Priority Date Filing Date
FI934134A FI107881B (fi) 1991-03-21 1993-09-21 Menetelmä Herpes simplex-rokotteen valmistamiseksi, joka sisältää HSV-glykoproteiinia GD ja 3-deasyloitua monofosforyylilipidi A:ta

Country Status (34)

Country Link
US (1) US6027730A (fi)
EP (1) EP0576478B2 (fi)
JP (1) JP3530526B2 (fi)
KR (1) KR100224329B1 (fi)
CN (2) CN1058191C (fi)
AP (1) AP298A (fi)
AT (1) ATE129160T1 (fi)
AU (1) AU650521B2 (fi)
BR (1) BR9205745A (fi)
CA (1) CA2106492C (fi)
CY (1) CY1936A (fi)
CZ (1) CZ280505B6 (fi)
DE (1) DE69205566T3 (fi)
DK (1) DK0576478T4 (fi)
ES (1) ES2081102T5 (fi)
FI (1) FI107881B (fi)
GB (1) GB9105992D0 (fi)
GR (1) GR3017884T3 (fi)
HK (1) HK1004525A1 (fi)
HU (1) HU218025B (fi)
IE (1) IE69560B1 (fi)
IL (1) IL101290A (fi)
MA (1) MA22471A1 (fi)
MX (1) MX9201245A (fi)
MY (1) MY110086A (fi)
NO (1) NO307499B1 (fi)
NZ (1) NZ242057A (fi)
PL (1) PL170059B1 (fi)
PT (1) PT100262B (fi)
SA (1) SA92120459B1 (fi)
SK (1) SK279190B6 (fi)
WO (1) WO1992016231A1 (fi)
YU (1) YU28392A (fi)
ZA (1) ZA922011B (fi)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
US6197311B1 (en) 1991-07-25 2001-03-06 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
GB9202933D0 (en) * 1992-02-12 1992-03-25 Smithkline Beecham Biolog Vaccines
US6620414B2 (en) 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
EP0684838A1 (en) * 1993-02-19 1995-12-06 Smithkline Beecham Corporation Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
ATE204762T1 (de) * 1993-03-23 2001-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
PT705109E (pt) * 1993-05-25 2001-02-28 American Cyanamid Co Adjuvantes para vacinas contra virus sinciciais respiratorios
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
ATE235514T1 (de) * 1994-12-28 2003-04-15 Univ Kentucky Monoklonaler anti-idiotypischer antikörper 3h1 aus maus
US6949244B1 (en) 1995-12-20 2005-09-27 The Board Of Trustees Of The University Of Kentucky Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
US20020041872A1 (en) 1996-04-12 2002-04-11 Malaya Chatterjee Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
US6235280B1 (en) 1996-04-12 2001-05-22 Malaya Chatterjee Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
US6468782B1 (en) 1996-12-05 2002-10-22 Quadrant Healthcare (Uk) Limited Methods of preserving prokaryotic cells and compositions obtained thereby
US6274143B1 (en) 1997-06-13 2001-08-14 Malaya Chatterjee Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10
US6355244B1 (en) 1997-11-17 2002-03-12 University Of Kentucky Research Foundation Methods and compositions for the treatment of psoriasis
US6692752B1 (en) * 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
GB9819898D0 (en) * 1998-09-11 1998-11-04 Smithkline Beecham Plc New vaccine and method of use
CA2347099C (en) 1998-10-16 2014-08-05 Smithkline Beecham Biologicals S.A. Adjuvant systems comprising an immunostimulant adsorbed to a metallic salt particle and vaccines thereof
US7026155B2 (en) 1999-02-02 2006-04-11 Regents Of The University Of California Method of reducing bacterial proliferation
EP1104767A1 (en) 1999-11-30 2001-06-06 Stichting Dienst Landbouwkundig Onderzoek Mono- and disaccharide derivatives containing both fatty acid ester and sulfate ester groups
US9273326B2 (en) 2004-04-30 2016-03-01 The Brigham And Women's Hospital, Inc. Tetracycline-regulated gene expression in HSV-1 vectors
KR101505496B1 (ko) 2004-09-22 2015-03-25 글락소스미스클라인 바이오로지칼즈 에스.에이. 스태필로코쿠스에 대한 예방접종에 사용하기 위한 면역원성 조성물
AU2006226458B2 (en) 2005-03-23 2012-08-30 Glaxosmithkline Biologicals S.A. Novel composition
EP3020411A1 (en) 2005-12-22 2016-05-18 GlaxoSmithKline Biologicals s.a. Vaccine
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
JP2009531387A (ja) 2006-03-30 2009-09-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
KR101696727B1 (ko) 2006-07-17 2017-01-16 글락소스미스클라인 바이오로지칼즈 에스.에이. 인플루엔자 백신
SI2068918T1 (sl) 2006-09-26 2012-09-28 Infectious Disease Res Inst Si - ep sestavek za cepljenje, ki vsebuje sintetiäśna pomagala
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PE20090146A1 (es) 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
WO2009000825A2 (en) 2007-06-26 2008-12-31 Glaxosmithkline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
EP3756684A1 (en) * 2009-05-22 2020-12-30 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
RU2732574C2 (ru) 2009-06-05 2020-09-21 Инфекшес Дизиз Рисерч Инститьют Синтетические глюкопиранозиллипидные адъюванты
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
AU2010333749B2 (en) * 2009-12-21 2015-07-30 The Brigham And Women's Hospital, Inc. Herpes simplex virus vaccines
EP2643014A4 (en) 2010-11-24 2015-11-11 Genocea Biosciences Inc HERPES SIMPLEX TYPE 2 VIRUS VACCINES: COMPOSITIONS AND METHODS FOR STIMULATING AN IMMUNE RESPONSE
US9821054B2 (en) * 2011-03-11 2017-11-21 Turnstone Limited Partnership Method of vaccination comprising a histone deacetylase inhibitor
CA2832307A1 (en) 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
US10206996B2 (en) 2011-08-22 2019-02-19 Nanobio Corporation Herpes simplex virus nanoemulsion vaccine
CA2885693C (en) 2011-11-23 2020-07-28 Genocea Biosciences, Inc. Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
NZ701881A (en) 2012-05-16 2016-10-28 Immune Design Corp Vaccines for hsv-2
WO2014107731A1 (en) 2013-01-07 2014-07-10 Biomedical Research Models, Inc. Therapeutic vaccines for treating herpes simplex virus type 2 infections
AU2014253791B2 (en) 2013-04-18 2019-05-02 Immune Design Corp. GLA monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US10350288B2 (en) 2016-09-28 2019-07-16 Genocea Biosciences, Inc. Methods and compositions for treating herpes
US11390650B2 (en) 2018-02-05 2022-07-19 The Brigham And Women's Hospital, Inc. Recombinant Herpes Simplex Virus-2 expressing glycoprotein B and D antigens
CA3208643A1 (en) 2021-01-18 2022-07-21 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4372945A (en) * 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) * 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US5110587A (en) * 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4762708A (en) * 1982-02-18 1988-08-09 University Patents, Inc. Materials and methods for herpes simplex virus vaccination
US5149660A (en) * 1982-02-18 1992-09-22 University Patents, Inc. Diagnostic reagents relating to herpes simplex virus
NZ209308A (en) * 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
US5171568A (en) * 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US5244792A (en) * 1984-04-06 1993-09-14 Chiron Corporation Expression of recombinant glyoprotein B from herpes simplex virus
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5554372A (en) * 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
WO1988002634A1 (en) * 1986-10-20 1988-04-21 Chiron Corporation Vaccine for use in the therapeutic treatment of hsv
US5149529A (en) * 1988-04-08 1992-09-22 Board Of Trustees Of Leland Chiron Corporation Compositions and treatment for herpes simplex
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
NZ230424A (en) * 1988-08-25 1992-05-26 Liposome Co Inc Liposomal composition comprising an externally disposed antigen
JP2955314B2 (ja) * 1988-10-27 1999-10-04 リージェンツ・オブ・ザ・ユニバーシティー・オブ・ミネソタ Ｉｌ―２含有リポソーム免疫アジュバント
US5597573A (en) * 1989-05-04 1997-01-28 Igen, Inc. Lipid-A analogs: new monosaccharide and disaccharide intermediates for eliciting therapeutic antibodies and for antitumor and antiviral activities
US5158939A (en) * 1989-07-21 1992-10-27 Wisconsin Alumni Research Foundation Method of stimulating the immune systems of animals and compositions useful therefor
AU651949B2 (en) * 1989-07-14 1994-08-11 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
ATE189702T1 (de) * 1990-08-01 2000-02-15 Res Corp Technologies Inc Das für das pferde herpes-virus typ 1 glykoprotein d, kodierende gen, sein genprodukt, antikörper und ihre verwendung
JP3005292B2 (ja) * 1990-08-02 2000-01-31 カイロン コーポレイション 単純ヘルペスウィルスのｖｐ１６のワクチン
GB9106048D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccines
US5196452A (en) * 1991-01-29 1993-03-23 Genelabs Incorporated Macrocyclic anti-viral compound and method
US5166173A (en) * 1991-01-29 1992-11-24 Genelabs Incorporated Method of treating herpes simplex virus infection
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
MY111880A (en) * 1992-03-27 2001-02-28 Smithkline Beecham Biologicals S A Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a
JP3755890B2 (ja) * 1992-06-25 2006-03-15 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） アジュバント含有ワクチン組成物
EP0684838A1 (en) * 1993-02-19 1995-12-06 Smithkline Beecham Corporation Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
ATE204762T1 (de) * 1993-03-23 2001-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
PT705109E (pt) * 1993-05-25 2001-02-28 American Cyanamid Co Adjuvantes para vacinas contra virus sinciciais respiratorios

Also Published As

Publication number Publication date
BR9205745A (pt) 1994-10-18
AU650521B2 (en) 1994-06-23
EP0576478B2 (en) 2001-04-18
EP0576478A1 (en) 1994-01-05
CN1101226C (zh) 2003-02-12
PT100262B (pt) 2001-05-31
NO307499B1 (no) 2000-04-17
AP9200368A0 (en) 1992-04-30
GR3017884T3 (en) 1996-01-31
US6027730A (en) 2000-02-22
IL101290A0 (en) 1992-11-15
WO1992016231A1 (en) 1992-10-01
HUT67052A (en) 1995-01-30
NO933343L (no) 1993-09-20
HK1004525A1 (en) 1998-11-27
CN1058191C (zh) 2000-11-08
SA92120459B1 (ar) 2005-06-14
AU1365792A (en) 1992-10-21
CA2106492C (en) 2003-12-09
JPH06505727A (ja) 1994-06-30
MY110086A (en) 1997-12-31
DE69205566D1 (en) 1995-11-23
PT100262A (pt) 1993-06-30
CN1065997A (zh) 1992-11-11
IE69560B1 (en) 1996-10-02
DE69205566T2 (de) 1996-04-18
SK279190B6 (sk) 1998-07-08
MX9201245A (es) 1992-10-01
CZ280505B6 (cs) 1996-02-14
IL101290A (en) 1996-07-23
AP298A (en) 1994-01-14
FI107881B (fi) 2001-10-31
YU28392A (sh) 1994-11-15
KR100224329B1 (ko) 1999-10-15
HU218025B (hu) 2000-05-28
DK0576478T3 (da) 1995-12-04
MA22471A1 (fr) 1992-10-01
ATE129160T1 (de) 1995-11-15
DK0576478T4 (da) 2001-07-23
IE920881A1 (en) 1992-09-23
ZA922011B (en) 1993-01-27
ES2081102T3 (es) 1996-02-16
NO933343D0 (no) 1993-09-20
JP3530526B2 (ja) 2004-05-24
HU9302645D0 (en) 1994-01-28
SK94693A3 (en) 1994-05-11
FI934134A0 (fi) 1993-09-21
GB9105992D0 (en) 1991-05-08
CY1936A (en) 1992-03-17
PL170059B1 (pl) 1996-10-31
CA2106492A1 (en) 1992-09-22
EP0576478B1 (en) 1995-10-18
DE69205566T3 (de) 2002-09-05
NZ242057A (en) 1993-12-23
CZ195893A3 (en) 1994-07-13
CN1201692A (zh) 1998-12-16
ES2081102T5 (es) 2001-09-01

Similar Documents

Publication Publication Date Title
FI934134A0 (fi) Herpes simplex-vaccin innehaollande hsv-glykoprotein gd och 3-deacylerad monofosforyllipid a
GB2215024B (en) Modular light strip
FI934668A (fi) Tillslutningssytem foer oevertaeckta kaerl och liknande
FI925427A (fi) Styrkrets och foerfarande foer transmissionsutgaong
FI934897A0 (fi) Syramodifierade polyhydriska alkoholhartsesterklibbmedel och vaermesmaeltbarakompositioner innehaollande dessa klibbmedel
FI930064A (fi) Anpassningsbar ekvalisator och mottagare
FI930874A0 (fi) Roerligt produktionssystem och en i systemet anvaendbar lastpall
FI925533A0 (fi) Tantal- eller niobbaserad perovskit och foerfarande foer framstaellning daerav
FI924747A0 (fi) Peg-imidat och proteinderivat daerav
FI921096A (fi) Vaesentligen icke-tvaerbundna maleinsyraanhydridmodifierade etenpolymerer och foerfarande foer deras framstaellning
FI934328A0 (fi) Foerfarande och anordning foer nqr-testning
FI912760A (fi) Skivfilter och filterelement foer skivfilter
FI930076A (fi) Cysteamin innehaollande permanentningskomposition och foerfarande
FI922004A (fi) Maetningsfoerfarande och maetanordning
FI922920A (fi) Separationsfoerfarande och anordning haerfoer
FI921741A (fi) En katalyt och belaeggningskomposition innehaollande densamma
FI924083A (fi) Spaenningsdeviationkompensator foer slaecktid foer vaexelriktare och omformare
FI934187A0 (fi) Icke-foervraengda polyetenskumstrukturer och framstaellningsfoerfarande
FI934325A0 (fi) Insekticid komposition och insekticida enheter
FI933359A0 (fi) Fodertillsatsaemne och foerfarande
FI923562A (fi) Vattenloesliga hartsbaserade belaeggningar och blaeck
FI925364A (fi) Foerfarande och anordning foer traodloes informationsoeverfoering
FI924767A (fi) Alkyleringsfoerfarande foer isoalkan-olefiner och katalysatorer foer detsamma
GB9004393D0 (en) A light
FI925857A0 (fi) Nytt konserveringssystem och komposition aendamaolsenlig foer konservering

Legal Events

Date Code Title Description
MA Patent expired